Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma
Multiple Myeloma (MM) remains an incurable disease due to high relapse rates and fast development of drug resistances. The introduction of monoclonal antibodies (mAb) has caused a paradigm shift in MM treatment, paving the way for targeted approaches with increased efficacy and reduced toxicities. N...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/21/5471 |
| _version_ | 1797468783688810496 |
|---|---|
| author | Ane Amundarain Fernando Pastor Felipe Prósper Xabier Agirre |
| author_facet | Ane Amundarain Fernando Pastor Felipe Prósper Xabier Agirre |
| author_sort | Ane Amundarain |
| collection | DOAJ |
| description | Multiple Myeloma (MM) remains an incurable disease due to high relapse rates and fast development of drug resistances. The introduction of monoclonal antibodies (mAb) has caused a paradigm shift in MM treatment, paving the way for targeted approaches with increased efficacy and reduced toxicities. Nevertheless, antibody-based therapies face several difficulties such as high immunogenicity, high production costs and limited conjugation capacity, which we believe could be overcome by the introduction of nucleic acid aptamers. Similar to antibodies, aptamers can bind to their targets with great affinity and specificity. However, their chemical nature reduces their immunogenicity and production costs, while it enables their conjugation to a wide variety of cargoes for their use as delivery agents. In this review, we summarize several aptamers that have been tested against MM specific targets with promising results, establishing the rationale for the further development of aptamer-based strategies against MM. In this direction, we believe that the study of novel plasma cell surface markers, the development of intracellular aptamers and further research on aptamers as building blocks for complex nanomedicines will lead to the generation of next-generation targeted approaches that will undoubtedly contribute to improve the management and life quality of MM patients. |
| first_indexed | 2024-03-09T19:12:18Z |
| format | Article |
| id | doaj.art-76e95113870742cba19d58d7f6c2e83d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T19:12:18Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-76e95113870742cba19d58d7f6c2e83d2023-11-24T04:04:56ZengMDPI AGCancers2072-66942022-11-011421547110.3390/cancers14215471Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple MyelomaAne Amundarain0Fernando Pastor1Felipe Prósper2Xabier Agirre3Center for Applied Medical Research (CIMA), IDISNA, University of Navarra, 31008 Pamplona, SpainCenter for Applied Medical Research (CIMA), IDISNA, University of Navarra, 31008 Pamplona, SpainCenter for Applied Medical Research (CIMA), IDISNA, University of Navarra, 31008 Pamplona, SpainCenter for Applied Medical Research (CIMA), IDISNA, University of Navarra, 31008 Pamplona, SpainMultiple Myeloma (MM) remains an incurable disease due to high relapse rates and fast development of drug resistances. The introduction of monoclonal antibodies (mAb) has caused a paradigm shift in MM treatment, paving the way for targeted approaches with increased efficacy and reduced toxicities. Nevertheless, antibody-based therapies face several difficulties such as high immunogenicity, high production costs and limited conjugation capacity, which we believe could be overcome by the introduction of nucleic acid aptamers. Similar to antibodies, aptamers can bind to their targets with great affinity and specificity. However, their chemical nature reduces their immunogenicity and production costs, while it enables their conjugation to a wide variety of cargoes for their use as delivery agents. In this review, we summarize several aptamers that have been tested against MM specific targets with promising results, establishing the rationale for the further development of aptamer-based strategies against MM. In this direction, we believe that the study of novel plasma cell surface markers, the development of intracellular aptamers and further research on aptamers as building blocks for complex nanomedicines will lead to the generation of next-generation targeted approaches that will undoubtedly contribute to improve the management and life quality of MM patients.https://www.mdpi.com/2072-6694/14/21/5471aptamersmultiple myelomatargeted therapies |
| spellingShingle | Ane Amundarain Fernando Pastor Felipe Prósper Xabier Agirre Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma Cancers aptamers multiple myeloma targeted therapies |
| title | Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma |
| title_full | Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma |
| title_fullStr | Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma |
| title_full_unstemmed | Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma |
| title_short | Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma |
| title_sort | aptamers a new therapeutic opportunity for the treatment of multiple myeloma |
| topic | aptamers multiple myeloma targeted therapies |
| url | https://www.mdpi.com/2072-6694/14/21/5471 |
| work_keys_str_mv | AT aneamundarain aptamersanewtherapeuticopportunityforthetreatmentofmultiplemyeloma AT fernandopastor aptamersanewtherapeuticopportunityforthetreatmentofmultiplemyeloma AT felipeprosper aptamersanewtherapeuticopportunityforthetreatmentofmultiplemyeloma AT xabieragirre aptamersanewtherapeuticopportunityforthetreatmentofmultiplemyeloma |